Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (5) : infectious diseases

Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate

Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate
07/27/2026 | Companies
Decoy Therapeutics Inc, a biotechnology company focused on developing Designable Multi-Antivirals (D-MAVs), has announced that one of its D-MAV candidates has demonstrated in vitro effectiveness against the wild-type Ebola Zaire virus during testing conducted at the Texas Biomedical Research...
antiviral platform, antiviral therapy, arenaviruses, biotechnology, biotechnology news, broad-spectrum antivirals, coronavirus, D-MAV, DCOY, Decoy Therapeutics, Democratic Republic of the Congo, Designable Multi-Antivirals, drug development, Ebola, Ebola Zaire virus, emerging viruses, FDA Tropical Disease Priority Review Voucher, filoviruses, IMP3ACT platform, in vitro study, infectious disease treatment, infectious diseases, Lassa fever virus, Marburg virus, pandemic preparedness, pharmaceutical research, Texas Biomedical Research Institute, Uganda, viral fusion machinery, viral research

Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty

Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty
01/15/2026 | Companies
Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States. During its presentation at Biotech Showcase 2026, the company outlined a forward-looking antiviral approach centered on...
antiviral drug development, basket trial, Biotech Showcase 2026, biotechnology, broad-spectrum antiviral, clinical research, COVID-19 variants, dengue fever, FDA IND application, global health, Hyundai Bioscience, infectious diseases, influenza, multi-viral treatment, pharmaceutical innovation, Phase 2 clinical trials, public health strategy, RSV, tripledemic, viral epidemics, virus prevention, Xafty

Clover Biopharma Advances Phase 2 Trial for RSV Combination Vaccines

Clover Biopharma Advances Phase 2 Trial for RSV Combination Vaccines
01/12/2026 | Companies
Clover Biopharmaceuticals, Ltd, a global biotechnology company with commercial-stage operations and a focus on developing innovative vaccines to protect lives and enhance public health worldwide, has announced the completion of first-participant enrollment in a Phase 2 clinical study in Australia....
Australia clinical trial, biotechnology company, clinical research, Clover Biopharmaceuticals, combination vaccines, global health, hMPV vaccine, immunogenicity, infectious diseases, older adults, Phase 2 clinical trial, PIV3 vaccine, prefusion-stabilized F protein, protein-based vaccines, respiratory vaccines, RSV vaccine, Trimer-Tag technology, vaccine development, vaccine safety

Living with HIV and Hepatitis B: A Story of Hope and Care in Thailand

Living with HIV and Hepatitis B: A Story of Hope and Care in Thailand
04/10/2025 | Companies
In 2019, 21-year-old Somchai from Thailand was dealing with two serious health conditions—he had both hepatitis B (HBV) and advanced HIV. “Because these two viruses are transmitted in similar ways through blood, it’s not unusual to see patients with both,” explains Dr. Anchalee Avihingsanon, the...
Asia, coinfection, community healthcare, Dr. Anchalee Avihingsanon, epidemic, global health, HBV, healthcare access, hepatitis B, HIV, HIV treatment, HIV-HBV, infectious diseases, medical research, patient care, public health, Somchai, Thai Red Cross, Thailand, viral infections

Ending the HIV Epidemic: Insights and Strategies for 2030

Ending the HIV Epidemic: Insights and Strategies for 2030
10/10/2024 | Companies
In the early 2000s, Dr. Shannon Hader was instrumental in the collaboration between the U.S. Centers for Disease Control and Prevention and the Zimbabwe Ministry of Health, which successfully provided HIV care to tens of thousands. After returning to the United States in 2006, she encountered a...
2030 goals, CDC, community-based care, discrimination, global health, health equity, health systems, HIV care, HIV epidemic, HIV testing, infectious diseases, innovative practices, prevention strategies, public health, stigma, treatment access, United Nations, Washington D.C.


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com